Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2014: Market Overview

384 views
296 views

Published on

Relapsing Multiple Sclerosis (RMS) @ http://www.researchmoz.us/relapsing-multiple-sclerosis-rms-pipeline-review-h1-2014-report.html

This report provides comprehensive information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

Published in: Healthcare, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
384
On SlideShare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2014: Market Overview

  1. 1. Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2014 Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2014 Summary Global Markets Directs, Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2014, provides an overview of the Relapsing Multiple Sclerosis (RMS)s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Relapsing Multiple Sclerosis (RMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Multiple Sclerosis (RMS) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Multiple Sclerosis (RMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Multiple Sclerosis (RMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Multiple Sclerosis (RMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Multiple Sclerosis (RMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Relapsing Multiple Sclerosis (RMS) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Relapsing Multiple Sclerosis (RMS) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Table Of Contents table Of Contents 2 list Of Tables 5 list Of Figures 6 introduction 7 global Markets Direct Report Coverage 7 relapsing Multiple Sclerosis (rms) Overview 8 therapeutics Development 9 pipeline Products For Relapsing Multiple Sclerosis (rms) - Overview 9 pipeline Products For Relapsing Multiple Sclerosis (rms) - Comparative Analysis 10 relapsing Multiple Sclerosis (rms) - Therapeutics Under Development By Companies 11 relapsing Multiple Sclerosis (rms) - Therapeutics Under Investigation By Universities/institutes 13 relapsing Multiple Sclerosis (rms) - Pipeline Products Glance 14 late Stage Products 14 Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2014
  2. 2. clinical Stage Products 15 early Stage Products 16 relapsing Multiple Sclerosis (rms) - Products Under Development By Companies 17 relapsing Multiple Sclerosis (rms) - Products Under Investigation By Universities/institutes 18 relapsing Multiple Sclerosis (rms) - Companies Involved In Therapeutics Development 19 f. Hoffmann-la Roche Ltd. 19 biogen Idec Inc. 20 sanofi 21 apitope International Nv 22 octapharma Ag 23 to-bbb Technologies Bv 24 meiji Seika Pharma Co., Ltd. 25 biocad 26 relapsing Multiple Sclerosis (rms) - Therapeutics Assessment 27 assessment By Monotherapy Products 27 assessment By Target 28 assessment By Mechanism Of Action 31 assessment By Route Of Administration 34 assessment By Molecule Type 36 drug Profiles 38 peginterferon Beta-1a - Drug Profile 38 product Description 38 mechanism Of Action 38 r&d Progress 38 alemtuzumab - Drug Profile 39 product Description 39 mechanism Of Action 39 r&d Progress 39 ocrelizumab - Drug Profile 42 product Description 42 mechanism Of Action 42 r&d Progress 42 minocycline - Drug Profile 45 product Description 45 mechanism Of Action 45 r&d Progress 45 immune Globulin (human) - Drug Profile 47 product Description 47 mechanism Of Action 47 r&d Progress 47 epigallocatechin Gallate - Drug Profile 49 product Description 49 mechanism Of Action 49 r&d Progress 49 biib-033 - Drug Profile 51 product Description 51 mechanism Of Action 51 r&d Progress 51 natalizumab - Drug Profile 53 product Description 53 mechanism Of Action 53 r&d Progress 53 atx-1467 - Drug Profile 55 product Description 55 mechanism Of Action 55 r&d Progress 55 2b3-201 - Drug Profile 56 product Description 56 mechanism Of Action 56 r&d Progress 56 interferon Beta-1a - Drug Profile 57 product Description 57 mechanism Of Action 57 r&d Progress 57 cp-9531 - Drug Profile 58 product Description 58 mechanism Of Action 58 r&d Progress 58 Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2014
  3. 3. relapsing Multiple Sclerosis (rms) - Recent Pipeline Updates 59 relapsing Multiple Sclerosis (rms) - Dormant Projects 73 relapsing Multiple Sclerosis (rms) - Discontinued Products 74 relapsing Multiple Sclerosis (rms) - Product Development Milestones 75 featured News & Press Releases 75 jan 06, 2014: Receptos Begins Enrollment Of Phase 3 Trial Of Rpc1063 In Relapsing Multiple Sclerosis 75 oct 03, 2013: Real-world Evidence Showed Superiority Of Novartis' Gilenya To Reduce Ms Relapse Rates Compared To Interferons Or Glatiramer Acetate 75 oct 03, 2013: Teva To Present Further Results Of Twenty-year Open-label Extension Study Of Glatiramer Acetate 20 Mg Daily For Relapsing-remitting Multiple Sclerosis 76 oct 01, 2013: New Data Analyses Show Significant Clinical And Mri Improvements With Plegridy 77 sep 03, 2013: Apitope Announces Positive Results From Clinical Trial Of Atx-ms-1467 In Relapsing Multiple Sclerosis 78 jul 19, 2013: Us And Eu Regulatory Authorities Accept Plegridy Marketing Applications For Review 79 jun 05, 2013: Redhill Biopharma Commences Patient Screening In Phase Iia Clinical Trial With Rhb-104 For Multiple Sclerosis 80 jun 05, 2013: Receptos Provides Update On Progress Of Lead Product Candidate Rpc1063 80 may 30, 2013: Teva Announces Fda Acceptance Of Snda For Higher Concentration Dose Of Copaxone 82 may 21, 2013: Biogen Idec Submits Application To Fda For Approval Of Plegridy In Multiple Sclerosis 82 appendix 84 methodology 84 coverage 84 secondary Research 84 primary Research 84 expert Panel Validation 84 contact Us 85 disclaimer 85 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Relapsing Multiple Sclerosis (RMS) - Pipeline Review, H1 2014

×